- Home
- NAVI vs EXEL Comparison
NAVI vs EXEL Comparison
Compare NAVI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- EXEL
- Stock Information
- Founded
- NAVI 1973
- EXEL 1994
- Country
- NAVI United States
- EXEL United States
- Employees
- NAVI N/A
- EXEL N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAVI Finance
- EXEL Health Care
- Exchange
- NAVI Nasdaq
- EXEL Nasdaq
- Market Cap
- NAVI 1.2B
- EXEL 9.8B
- IPO Year
- NAVI N/A
- EXEL 2000
- Fundamental
- Price
- NAVI $13.51
- EXEL $36.17
- Analyst Decision
- NAVI Hold
- EXEL Buy
- Analyst Count
- NAVI 7
- EXEL 18
- Target Price
- NAVI $13.64
- EXEL $37.59
- AVG Volume (30 Days)
- NAVI 684.8K
- EXEL 2.2M
- Earning Date
- NAVI 04-30-2025
- EXEL 05-13-2025
- Dividend Yield
- NAVI 4.88%
- EXEL N/A
- EPS Growth
- NAVI N/A
- EXEL 170.77
- EPS
- NAVI 0.52
- EXEL 1.76
- Revenue
- NAVI $699,000,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- NAVI N/A
- EXEL $5.78
- Revenue Next Year
- NAVI N/A
- EXEL $10.94
- P/E Ratio
- NAVI $25.31
- EXEL $20.64
- Revenue Growth
- NAVI N/A
- EXEL 18.50
- 52 Week Low
- NAVI $10.53
- EXEL $20.14
- 52 Week High
- NAVI $16.97
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- NAVI 65.32
- EXEL 43.89
- Support Level
- NAVI $12.53
- EXEL $34.90
- Resistance Level
- NAVI $13.05
- EXEL $40.26
- Average True Range (ATR)
- NAVI 0.45
- EXEL 1.21
- MACD
- NAVI 0.20
- EXEL -0.19
- Stochastic Oscillator
- NAVI 98.37
- EXEL 23.69
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.